WO2001074136A3 - Telomerase inhibitor polynucleotides - Google Patents

Telomerase inhibitor polynucleotides Download PDF

Info

Publication number
WO2001074136A3
WO2001074136A3 PCT/US2001/010476 US0110476W WO0174136A3 WO 2001074136 A3 WO2001074136 A3 WO 2001074136A3 US 0110476 W US0110476 W US 0110476W WO 0174136 A3 WO0174136 A3 WO 0174136A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide
telomerase inhibitor
inhibitor polynucleotides
certain modified
polynucleotides
Prior art date
Application number
PCT/US2001/010476
Other languages
French (fr)
Other versions
WO2001074136A2 (en
Inventor
Sergei M Gryaznov
Ronald Pruzan
Scott L Weinrich
Original Assignee
Geron Corp
Sergei M Gryaznov
Ronald Pruzan
Scott L Weinrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp, Sergei M Gryaznov, Ronald Pruzan, Scott L Weinrich filed Critical Geron Corp
Priority to AU2001249723A priority Critical patent/AU2001249723A1/en
Publication of WO2001074136A2 publication Critical patent/WO2001074136A2/en
Publication of WO2001074136A3 publication Critical patent/WO2001074136A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Abstract

Polynucleotide inhibitors and methods for inhibiting telomerase activity are provided. The polynucleotide inhibitors are substantially complementary to a portion of the human telomerase RNA component in a non-template region between nucleotide 137 and nucleotide 179 and contain certain modified nucleotide residues or certain modified linkages between adjacent nucleotides.
PCT/US2001/010476 2000-03-31 2001-03-30 Telomerase inhibitor polynucleotides WO2001074136A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001249723A AU2001249723A1 (en) 2000-03-31 2001-03-30 Telomerase inhibitor polynucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54011900A 2000-03-31 2000-03-31
US09/540,119 2000-03-31

Publications (2)

Publication Number Publication Date
WO2001074136A2 WO2001074136A2 (en) 2001-10-11
WO2001074136A3 true WO2001074136A3 (en) 2003-10-30

Family

ID=24154082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010476 WO2001074136A2 (en) 2000-03-31 2001-03-30 Telomerase inhibitor polynucleotides

Country Status (2)

Country Link
AU (1) AU2001249723A1 (en)
WO (1) WO2001074136A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070112295A (en) 1999-09-10 2007-11-22 제론 코포레이션 Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CA2478681A1 (en) * 2001-10-22 2003-05-01 University Of Rochester Telomerase interference
EP1432725A4 (en) * 2002-02-20 2005-03-30 Sirna Therapeutics Inc RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2014051519A1 (en) 2012-09-25 2014-04-03 Agency For Science, Technology And Research Telomerase inhibitors for use in therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583016A (en) * 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
WO1998028442A1 (en) * 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583016A (en) * 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
WO1998028442A1 (en) * 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAMILTON SUSAN E ET AL: "Cellular delivery of peptide nucleic acids and inhibition of human telomerase.", CHEMISTRY & BIOLOGY (LONDON), vol. 6, no. 6, June 1999 (1999-06-01), pages 343 - 351, XP002242127, ISSN: 1074-5521 *
NORTON J C ET AL: "INHIBITION OF HUMAN TELOMERASE ACTIVITY BY PEPTIDE NUCLEIC ACIDS", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 14, no. 5, May 1996 (1996-05-01), pages 615 - 619, XP001023086, ISSN: 0733-222X *
PITTS ANNE E ET AL: "Inhibition of human telomerase by 2'-O-methyl-RNA.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 20, Sept. 29, 1998, pages 11549 - 11554, XP002242128, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2001074136A2 (en) 2001-10-11
AU2001249723A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
GR3024597T3 (en) 7-deazapurine modified oligonucleotides
CA2278715A1 (en) Aminooxy-modified oligonucleotides
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
HK1154590A1 (en) Bicyclonucleoside oligonucleotide analogue
HK1044545A1 (en) Human beta-secretase enzyme, inhibitors and their compositions and uses
EP0781293A4 (en) Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides
BG106056A (en) Use of phthalazine derivatives
IL127031A0 (en) Methods for recombination of polynucleotide sequences using random or defined primers
CA2310854A1 (en) Isolation and identification of novel polymerases
IL145778A0 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
WO2004044133A3 (en) Modified oligonucleotides for use in rna interference
CA2177732A1 (en) Antisense oligonucleotides having tumorigenicity-inhibiting activity
DE69806003T2 (en) DNA POLYMERASES THAT HAVE IMPROVED ABILITY TO INSTALL MARKED NUCLEOTIDES
WO2001092512A3 (en) Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides
AU2001293122A1 (en) Surface treatment for improved hardness and corrosion resistance
HUP0301622A3 (en) Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
WO2001074136A3 (en) Telomerase inhibitor polynucleotides
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
EP1102786A4 (en) Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
DE69833112D1 (en) Rna polymerase
HK1048318A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors.
WO2001040521A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU7733200A (en) Compositions and methods for reducing oligonucleotide hybridization and priming specificity
AU6795201A (en) Nucleic acid sequences and methods for the modification of plant gene expression
IL134083A0 (en) Process of producing transgenic plants in which flowering is inhibited, and dna sequences used in said process

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP